Research map: Glowing evidence: radiation shines in early NLPHL

Back to the article

Papers in this map

  1. Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation · Zhen Fan · 2003 · 348 citations · Cited by this paper
  2. Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry · 2026 · Related
  3. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma · Michelle A. Fanale · 2017 · 89 citations · Cited by this paper
  4. Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development · 2026 · Related
  5. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma · Michael Sargent Binkley · 2024 · 22 citations · Cited by this paper
  6. Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia · 2026 · Related
  7. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry · Daniel L. Molin · 2017 · 21 citations · Cited by this paper
  8. Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q · 2026 · Related
  9. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group · Dennis Alexander Eichenauer · 2019 · 21 citations · Cited by this paper
  10. Reframing Hematologic and Thrombovascular Care for Transgender and Gender-Diverse Individuals: A Scoping Review · 2026 · Related
  11. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi · Manuel Gotti · 2023 · 13 citations · Cited by this paper
  12. Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant · 2026 · Related
  13. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies · Dennis Alexander Eichenauer · 2023 · 12 citations · Cited by this paper
  14. Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion dependent thalassemia in LMICs · 2026 · Related
  15. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group · Dennis Alexander Eichenauer · 2022 · 11 citations · Cited by this paper
  16. The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach · 2026 · Related
  17. Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas · Katherine E. Lake · 2025 · 1 citation · Cited by this paper
  18. A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia · 2026 · Related
  19. In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway · 2026 · Related

Source: OpenAlex (CC0)